Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Investor Presentation (February 2020)
15 slides from Optiscan Imaging's investor presentation, Feb 28, 2020
Slide 1: Optiscan Imaging Ltd (ASX:OIL)
For personal use only Optiscan Imaging Ltd (ASX:OIL) Enabling “Real-time Virtual Biopsy” for Human Cancer Screening and Surgical Margin Detection
Slide 2: Notice
Notice For personal use only This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) as at 28 February 2020. The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain all of the information which a
Slide 3: Notice
Notice For personal use only Not an offer or financial product advice This presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This presentation does not satisfy the disclosure requirement
Slide 4: Corporate Snapshot
Corporate Snapshot For personal use only Board Total Securities on Issue Darren Lurie – Executive Chairman ▪ 477,778,800 Ordinary Shares B.LLB (Hons) and B.COM (Hons) ▪ 25,600,000 unlisted options Former Group CFO and Head of Corporate Development for EduCo International (an investee company of Bari
Slide 5: Optiscan Introduction - Technology
OPTISCAN Introduction - Technology For personal use only 4.7 mm Optiscan Technology diameter • Successful Development of hand-held Confocal Microscope for Medical and Research Imaging • World-leading and Patent Protected Technology • Real-time “Virtual Biopsy”, visualisation of human living tissue •
Slide 6: Optiscan's Future: Enabling Real Time Virtual Biopsy
Optiscan’s Future: Enabling “Real Time Virtual Biopsy” For personal use only InVivage® Optiscan’s Clinical Device • Screening, Early Cancer Diagnosis and Targeted Biopsies • Tumour margin detection in Cancer Surgery • Initial Target Application: Oral Cancer 450,000 Oral and Oropharyngeal cancer case
Slide 7: New InVivage User Interface Designed for Doctors
New InVivage® User Interface Designed for Doctors For personal use only Squamous epithelial cells and taste bud papillae in tongue (0.5mm x 0.5mm view)
Slide 8: Optiscan – FY2020 Progress
OPTISCAN – FY2020 Progress For personal use only 3 Oral Cancer Studies and Trials: • Memorial Sloan Kettering Cancer Centre in New York (“MSK”) (on-going) • Melbourne Dental School in collaboration with Peter MacCallum Cancer Centre, Royal Melbourne Hospital, MSK and Australian Centre for Oral Oncol
Slide 9: Optiscan – Steps for US Approval to Market Device
OPTISCAN – Steps for US Approval to Market Device For personal use only United States Food Pre-Submission meeting with FDA in the USA - Jan 2020 Completed and Drug 450,000 Administration (FDA) Oral and 510(K) Submission Supplemental Q-Sub (Request for Feedback) document being Commenced prepared for
Slide 10: Breast Cancer - Most Common Cancer in Women
Breast Cancer - Most Common Cancer in Women For personal use only The number of breast cancer cases and defined cancer centres represent a large target market. 20-30% of lumpectomy patients currently require repeat surgery with current practice (histopathology analysis) often taking up to 3-4 days p
Slide 11: Optiscan - Breast Cancer Surgery
Optiscan - Breast Cancer Surgery For personal use only Intraoperative Assessment of Breast Cancer Surgical Margin Normal Breast Tissue • Goal: Assist breast surgeons and pathologists to provide real-time cellular assessment of surgical margin. • Benefits: Reduce risk of residual tumour, need for rep
Slide 12: Zeiss CONVIVO – Carl Zeiss Meditec Collaboration
ZEISS CONVIVO® – CARL ZEISS MEDITEC (CZM) COLLABORATION For personal use only ZEISS CONVIVO® 297,000 • Target Application: Tumour margin detection in Brain Brain and CNS Cancer surgery cancer cases • Current 2nd half FY20 orders of at least $450k with on- p.a. going discussions re further revenue op
Slide 13: Optiscan Research Device: Development of New Applications
OPTISCAN Research Device: Development of New Applications For personal use only Working in collaboration with CSIRO and Monash and Michigan Universities for new applications in 3D Tissue Culture and Anterior Cruciate Ligament (ACL) imaging respectively • 3D tissue culture imaging application develop
Slide 14: Distributor Strategy for Research Markets in China and North America
Distributor Strategy for Research Markets in China and North America For personal use only • New multi-distributor model in China with appointment of exclusive distributor in Southern and Western China. ▪ South and West China: Guangzhou Yunxing (Purple and Blue) ▪ East China: Biotimes Technology Lim
Slide 15: Summary
Summary For personal use only ➢ Optiscan Device developed for “Real-time Virtual Biopsy” for Human Cancer Screening and Surgery • Button control features for single-handed operation unique to InVivage ➢ Jan 2020: 510(k) Pre-Submission Meeting with FDA for Oral Cancer ➢ Preparing documentation and ar
Optiscan Imaging — Investor Presentation (February 2020) on 6ix